These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

997 related articles for article (PubMed ID: 1681750)

  • 1. Dopamine in schizophrenia: a review and reconceptualization.
    Davis KL; Kahn RS; Ko G; Davidson M
    Am J Psychiatry; 1991 Nov; 148(11):1474-86. PubMed ID: 1681750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroleptics, dopamine, and schizophrenia.
    Pickar D
    Psychiatr Clin North Am; 1986 Mar; 9(1):35-48. PubMed ID: 2870480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of metabolic perturbation on plasma homovanillic acid in schizophrenia. Relationship to prefrontal cortex volume.
    Breier A; Davis OR; Buchanan RW; Moricle LA; Munson RC
    Arch Gen Psychiatry; 1993 Jul; 50(7):541-50. PubMed ID: 8317948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-regulation of central dopamine receptors in schizophrenia.
    Zemlan FP; Hitzemann RJ; Hirschowitz J; Garver DL
    Am J Psychiatry; 1985 Nov; 142(11):1334-7. PubMed ID: 2865903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine, the prefrontal cortex and schizophrenia.
    Knable MB; Weinberger DR
    J Psychopharmacol; 1997; 11(2):123-31. PubMed ID: 9208376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma homovanillic acid as an index of central dopaminergic activity: studies in schizophrenic patients.
    Pickar D; Breier A; Kelsoe J
    Ann N Y Acad Sci; 1988; 537():339-46. PubMed ID: 2904783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenesis of schizophrenia: Part II. Temporo-frontal two-step hypothesis.
    Kurachi M
    Psychiatry Clin Neurosci; 2003 Feb; 57(1):9-15. PubMed ID: 12519449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurobiology of dopamine in schizophrenia.
    Guillin O; Abi-Dargham A; Laruelle M
    Int Rev Neurobiol; 2007; 78():1-39. PubMed ID: 17349856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspectives on a time-dependent model of neuroleptic action.
    Pickar D
    Schizophr Bull; 1988; 14(2):255-68. PubMed ID: 2904694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine and schizophrenia.
    Crow TJ; Johnstone EC; Longden A; Owen F
    Adv Biochem Psychopharmacol; 1978; 19():301-9. PubMed ID: 29450
    [No Abstract]   [Full Text] [Related]  

  • 11. Dopamine in schizophrenia.
    Heritch AJ
    Am J Psychiatry; 1992 Nov; 149(11):1620-1. PubMed ID: 1415847
    [No Abstract]   [Full Text] [Related]  

  • 12. Do we still believe in the dopamine hypothesis? New data bring new evidence.
    Abi-Dargham A
    Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S1-5. PubMed ID: 14972078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into the biology of schizophrenia through the mechanism of action of clozapine.
    Brunello N; Masotto C; Steardo L; Markstein R; Racagni G
    Neuropsychopharmacology; 1995 Nov; 13(3):177-213. PubMed ID: 8602893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent psychosis after reduction in pre- and post-synaptic dopaminergic function.
    Wolkin A; Duncan E; Sanfilipo M; Wieland S; Cooper TB; Rotrosen J
    J Neural Transm Gen Sect; 1994; 95(1):49-61. PubMed ID: 7857586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hypofrontality and negative symptoms in schizophrenia: synthesis of anatomic and neuropsychological knowledge and ecological perspectives].
    Semkovska M; Bédard MA; Stip E
    Encephale; 2001; 27(5):405-15. PubMed ID: 11760690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine receptors and the dopamine hypothesis of schizophrenia.
    Seeman P
    Synapse; 1987; 1(2):133-52. PubMed ID: 2905529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The involvement of 5-HT1a serotonin receptors in the pathophysiology and pharmacotherapy of schizophrenia].
    Maćkowiak M; Czyrak A; Wedzony K
    Psychiatr Pol; 2000; 34(4):607-21. PubMed ID: 11059260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurochemical and neural mechanisms of positive and negative symptoms in schizophrenia.
    Pickar D; Litman RE; Konicki PE; Wolkowitz OM; Breier A
    Mod Probl Pharmacopsychiatry; 1990; 24():124-51. PubMed ID: 1970851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Biological markers in schizophrenia].
    Lembreghts M; Ansseau M
    Encephale; 1993; 19(5):501-23. PubMed ID: 8306920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment.
    Pickar D; Labarca R; Doran AR; Wolkowitz OM; Roy A; Breier A; Linnoila M; Paul SM
    Arch Gen Psychiatry; 1986 Jul; 43(7):669-76. PubMed ID: 3718170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.